PET Oncological Radiopharmaceuticals: Current Status and Perspectives

Molecular imaging is the visual representation of biological processes that take place at the cellular or molecular level in living organisms. To date, molecular imaging plays an important role in the transition from conventional medical practice to precision medicine. Among all imaging modalities, positron emission tomography (PET) has great advantages in sensitivity and the ability to obtain absolute imaging quantification after corrections for photon attenuation and scattering. Due to the ability to label a host of unique molecules of biological interest, including endogenous, naturally occurring substrates and drug-like compounds, the role of PET has been well established in the field of molecular imaging. In this article, we provide an overview of the recent advances in the development of PET radiopharmaceuticals and their clinical applications in oncology.

Automated summary

Molecular imaging is a visual method used to study biological processes at the cellular or molecular level in living organisms. PET, among all imaging modalities, has significant advantages in sensitivity and quantification of imaging after corrections. PET, with the ability to label various biological molecules, has been widely used in molecular imaging. This article provides an overview of the recent advances in PET radiopharmaceuticals and their clinical applications in oncology.